The UK Medicines and Healthcare Products Regulatory Agency (MHRA) has published a presentation on the re-purposing of established medicines mentioning how in silico approaches play a role.
The short presentation states “Identifying re-purposing opportunities comes from a variety of processes including knowledge mining of existing scientific databases, in silico approaches, in vitro and in vivo experiments, clinical observations, epidemiology and post-hoc analysis.”
The benefits of in silico approaches are being mentioned more and more by Regulators, an indication of the change in the healthcare industry in general.
The full presentation of the MHRA’s STAMP committee can be found here.
